This study was aimed to compare with previous results (Grillot et al., 1994), the efficacy of @entity4509 adaptive optimal control in a geriatric hospital. @entity1 : During six months, 32 @entity1 (aged of 82 +/- 8 years) were included versus 51 during two years (aged of 80 +/- 5). The mean age was not different between the two populations (NS, Student test). They received @entity4509 initial dosage of 17.7 +/- 5.1 mg/kg/d (vs 13.3 +/- 3.5 for the reference study) and maintenance dosage of 15.1 +/- 4.8 mg/kg/d (vs 11.8 +/- 5.1 for the reference study). METHOD: Two efficacy outcomes ( @entity4803 ) and 1 @entity137 outcome (T) were taken into account: E1 estimated the effect of adaptive control on maximal drug level, E2: overall recovery. @entity137 outcome was used: T the nephrotoxicity (increasing creatinin  mia over 44 mumol/l). RESULTS: All the results are given versus the reference study. 57.6% versus 29.4% of adaptive strategy were once-a-day. E1: Chi square test show that initial dosage and maintenance dosage are greater our study than the previous one (p < 0.05: 78.8% versus 5.9% for initial dosage, 84.4% versus 13.8% for maintenance dosage). E2: 73.6% overall of recovery versus 77% (NS, Chi square test). T: 94% versus 85% (p < 0.05, Chi square test) of creatininemia variation are lower than 44 mumol/l. Duration of treatment is 9.8 +/- 4.8 versus 15 +/- 9 days (p < 0.5, Student test). CONCLUSIONS: Once-a-day strategy in @entity4509 therapeutic regimen is no more efficient but decreases @entity137 and duration treatment.

[Efficacy and XXXX of aminoglycoside therapy in the elderly: combined effect of both once-daily regimen and therapeutic drug monitoring].

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity4803 :: ('6080;6044', 'Gene') :: ['E1 and E2'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity'] @entity4509 :: ('MESH:D000583', 'Chemical') :: ['amikacin']
@entity137 :: (MESH:D064420,Disease) :: ['toxicity']
